Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ptc Therapeutics Mp Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently navigating 2 pending office actions. This volume of activity is distributed across 2 distinct examiners, indicating a varied approach to the prosecution of their biological and pharmaceutical innovations. The presence of 2 distinct art units further suggests that the portfolio covers a range of technical sub-specialties within the broader biotech field.
The distribution of work shows that no single examiner dominates the pending caseload, as the busiest examiner, MOU, LIYUAN, is responsible for 1 busiest examiner pending office action. This means that the current office actions are split between different individuals, requiring practitioners to adapt to multiple examination styles simultaneously. Managing these 2 pending office actions involves coordinating across different administrative and technical boundaries within the patent office.
The alignment of 2 distinct examiners with 2 distinct art units reflects a one-to-one ratio for the current pending matters. This structure implies that each examiner is operating within a different technical framework, potentially leading to different prosecution timelines or requirements for each asset. Practitioners should monitor the specific tendencies of MOU, LIYUAN and the other assigned examiner to ensure that both of the 2 pending office actions are addressed effectively.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| GAUGER, PAUL RANDALL | 1 | 56.0% | +12.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17764003 | METHODS FOR TREATING HYPERPHENYLALANINEMIA | GAUGER, PAUL RANDALL | 34d |
| 17794357 | METHODS FOR TREATING PARKINSON'S DISEASE WITH SEPIAPTERIN | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17794357 | METHODS FOR TREATING PARKINSON'S DISEASE WITH SEPIAPTERIN | MOU, LIYUAN | 1628 | §102§103DP | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17764003 | METHODS FOR TREATING HYPERPHENYLALANINEMIA | GAUGER, PAUL RANDALL | 1629 | §103DP | Final Rejection | 34d | Pending | Mar 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial